Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy

1. Martínez, C.
2. Díaz-López, A.
3. Rodriguez-Calvillo, M.
4. García-Sanz, R.
5. Terol, M.J.
6. Pérez-Ceballos, E.
7. Jiménez, M.J.
8. Cantalapiedra, A.
9. Domingo-Domenech, E.
10. Rodriguez, M.J.
11. Sampol, A.
12. Espeso, M.
13. López, F.-J.
14. Briones, J.
15. García, J.F.
16. Sureda, A.